CliffBio
small molecule

TAVALISSE

FOSTAMATINIB DISODIUM

Loss of exclusivityJuly 2032latest FDA-listed patent expiry
CompanyRigel Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameTAVALISSE
Active ingredientFOSTAMATINIB DISODIUM
StrengthEQ 150MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2018
Marketing statusRX

Listed patents

PatentExpiresType
8771648July 2032product
8951504July 2032use U-2294
7449458September 2031substance
8263122November 2030product
8652492November 2028product
9283238June 2026use U-2294
8163902June 2026substance
8912170June 2026use U-2294
8445485June 2026product
7989448June 2026substance
7538108March 2026substance
8211889January 2026substance
RE48898January 2026product
9266912January 2026use U-2294

More from Rigel Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TAVALISSE patent cliff — loss of exclusivity July 2032 | CliffBio